RESULTS
Base case scenario
Compared to ICS alone, SCIT + ICS administered over three years in a
10-year time horizon would avert a total of 847 exacerbations per 1,000
patients treated. These results along with medication discontinuation
would generate 0.37 additional QALYs (3.7 months) and additional $836
costs per patient. These clinical gains are projected to come at a
higher total cost resulting from the additional cost of SCIT
administration in the first three years of the model (76.7%). Only a
small proportion of these costs (5.2%) would be compensated through
savings in costs associated to ED visits and hospitalizations. These
results yielded an ICER below a WTP threshold of $18,125 USD per
additional QALY making the SCIT+ICS cost-effective (Table 2).